Lymph Node Surgery Approaches for Lung Cancer After Chemo-Immunotherapy
Part of Cancer, Lungs & breathing clinical trials.
This study compares two surgical approaches for removing lymph nodes in the chest after you've completed chemotherapy and immunotherapy for non-small cell lung cancer. The goal is to determine which approach works best while keeping you as safe as possible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–74 years old
- Completed neoadjuvant chemotherapy combined with a PD-1 inhibitor (immunotherapy)
- Stage IIA–IIIB non-small cell lung cancer without EGFR mutations or ALK rearrangements
- Good heart and lung function (FEV1 >1.0 L or DLCO >40% predicted)
- Able to tolerate a standard lobe removal surgery (lobectomy)
- No prior chest surgery on the same side or prior chest radiation
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach for people with certain advanced non-small cell lung cancer (NSCLC) that has spread to lymph nodes in the chest but might still be removed. It combines a short course of high-precision radiation, immunotherapy (sintilimab), and standard chemotherapy before surgery to see if it can improve outcomes.
This trial compares two surgical approaches for advanced lung cancer (stage IIA-IIIB) after patients have already received immunotherapy and chemotherapy. Researchers want to see if removing a smaller portion of the lung (sub-lobectomy) works as well as removing an entire lobe (lobectomy), potentially reducing side effects while fighting cancer.
This study looks at whether removing lymph nodes from the opposite side of the chest during surgery can help people with advanced lung cancer that has spread to the lymph nodes in the middle of the chest. It may offer a more thorough treatment for patients who are healthy enough for surgery.
This trial compares removing fewer lymph nodes during surgery for early-stage non-small cell lung cancer. It is for people with a small tumor (2 cm or less) that has both solid and ground-glass parts.
This trial looks at complications from removing lymph nodes during surgery for non-small cell lung cancer. It may help doctors understand how to make surgery safer.
This trial compares two surgical approaches for people with a single small, noncancer-looking lung nodule (a GGN) that is diagnosed as very early lung cancer. It aims to see whether removing mediastinal lymph nodes—or leaving them alone—can lead to better outcomes with less harm.
Hear when a new Stage IIA-IIIB NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.